Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : View from the Center and Left -- Ignore unavailable to you. Want to Upgrade?

To: JohnM who wrote (175536)	11/7/2011 3:22:36 PM
From: Steve Lokness	Respond to of 541114

<<<< It's one of the more frequent flaws with data to read so called "real" data wrong>>>>> I'm sure not conflating two things! All that I did is post a comment made this morning in a press release and wondering why it doesn't square with what I had previously believed. I posted the entire paragraph - just so someone wouldn't claim I was distorting the press release comment.

To: JohnM who wrote (175536)	11/7/2011 4:03:45 PM
From: Steve Lokness	Read Replies (1) \| Respond to of 541114

John; Here is the complete press release; HOPKINTON, Mass., Nov. 7, 2011 /PRNewswire via COMTEX/ -- Caliper Life Sciences, Inc. (NASDAQ: CALP), a leading provider of tools and services for life science companies, today announced that Kevin Hrusovsky, President and CEO of Caliper delivered a keynote address at the BioConference Live event, which was held on October 26, and participated in the Personalized Medicine Panel during the World Health Forum on October 27 held at Harvard Medical School. The keynote titled, "A Revolution in Personalized Medicine - from Concept to Reality," highlighted the "sick" state of our current healthcare system, given the high cost of care and the lack of effective result for the patient. The keynote described what aspects of medical innovation are working and where excess treatment may actually be harmful to the patient. For example, on average only 25 percent of oncology therapeutic treatments are effective, and all patients are potentially harmed by the side effects of disease treatment. This forward looking presentation provided a view to the tools and techniques that will transform healthcare, focusing on innovative technologies in areas like genomic analysis, biomarkers, and imaging that will improve the ability to detect disease at earlier levels and determine the appropriate individualized treatments necessary to ensure the most beneficial patient outcome. Hrusovsky also described advancements in biotherapeutics, targeted small molecules, and regenerative medicine that will provide physicians with better treatment options for their patients. "Despite the trillions of dollars spent on medical research, a child born today has a shorter life expectancy than his or her parent," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. "The practice of medicine today is reactionary and more appropriately described as 'sick care' instead of 'health care.' At Caliper, we are committed to developing and commercializing disruptive technologies that improve the quality and length of life for all humankind, creating a revolution in healthcare that enables individualized treatment in a way that is economically sustainable."